Back

Spatial Transcriptomics Reveals a Conserved Border Niche and Etiology-Associated Immune Rewiring in Hepatocellular Carcinoma

Bae, S.; Choi, H.; Hong, S. Y.; Choi, Y.; Lee, K. W.; Na, K. J.; Hong, S. K.

2026-06-05 cancer biology
10.64898/2026.06.02.729569 bioRxiv
Show abstract

Background and AimsThe tumor-stroma interface in hepatocellular carcinoma (HCC) harbors critical intercellular interactions that shape immune evasion and treatment response, yet its spatial architecture remains poorly characterized across etiologies. Whether hepatitis B virus (HBV)-related and non-B non-C (NBNC) HCC share conserved border niche features or exhibit etiology-specific microenvironment programs is unknown. We aimed to spatially resolve the tumor boundary ecosystem and identify etiology-associated signaling networks with translational relevance. Approach and ResultsWe performed 10x Visium spatial transcriptomics on 11 HCC specimens (7 HBV, 4 NBNC) and applied a machine-learning pipeline integrating CancerFinder and SpaceFlow to define tumor, boundary, and stromal domains. Across etiologies, the boundary zone showed a recurrent desmoplastic niche characterized by cancer-associated fibroblast, tumor-associated macrophage, and tumor endothelial cell accumulation with collagen-integrin extracellular matrix remodeling, including COL1A1-ITGA11 and COL4A1-ITGAV. Etiology-associated differences were observed in the organization of border-zone signaling programs. In representative HBV-related sections, CCL19-CCR7 signaling showed a comparatively restricted, endothelial-skewed topology, whereas representative NBNC sections showed broader inflammatory ligand-receptor networks with elevated NF-kB-associated pathway activity. ConclusionsThe HCC tumor-stroma border harbors a recurrent desmoplastic niche upon which etiology-associated immune regulatory programs may be superimposed. These findings generate spatial hypotheses relevant to etiology-informed biomarker development and future therapeutic stratification.

Matching journals

The top 12 journals account for 50% of the predicted probability mass.

1
Journal of Hepatology
21 papers in training set
Top 0.1%
9.6%
2
The Journal of Pathology
26 papers in training set
Top 0.1%
7.8%
3
Genome Medicine
183 papers in training set
Top 0.4%
6.7%
4
JHEP Reports
11 papers in training set
Top 0.1%
4.3%
5
Gut
40 papers in training set
Top 0.2%
4.0%
6
Scientific Reports
3612 papers in training set
Top 34%
3.2%
7
Frontiers in Oncology
103 papers in training set
Top 1%
3.2%
8
Communications Medicine
113 papers in training set
Top 1%
3.2%
9
Hepatology
22 papers in training set
Top 0.2%
2.7%
10
eBioMedicine
183 papers in training set
Top 1%
2.6%
11
Nature Communications
5641 papers in training set
Top 40%
2.4%
12
PLOS Computational Biology
1863 papers in training set
Top 12%
2.4%
50% of probability mass above
13
Frontiers in Immunology
638 papers in training set
Top 5%
2.1%
14
PLOS ONE
5266 papers in training set
Top 45%
2.1%
15
Advanced Science
286 papers in training set
Top 4%
2.1%
16
Cell Reports Medicine
153 papers in training set
Top 2%
2.0%
17
Cell Communication and Signaling
51 papers in training set
Top 0.5%
1.7%
18
Journal of Translational Medicine
57 papers in training set
Top 0.8%
1.7%
19
Cancers
213 papers in training set
Top 3%
1.7%
20
Journal of Neuroinflammation
61 papers in training set
Top 0.9%
1.5%
21
iScience
1154 papers in training set
Top 26%
1.1%
22
Frontiers in Bioinformatics
49 papers in training set
Top 0.9%
1.1%
23
Cell Death Discovery
58 papers in training set
Top 1.0%
1.1%
24
Cells
249 papers in training set
Top 6%
1.0%
25
BMC Cancer
67 papers in training set
Top 2%
1.0%
26
JCI Insight
277 papers in training set
Top 7%
1.0%
27
Molecular Therapy Oncology
10 papers in training set
Top 0.2%
1.0%
28
Frontiers in Cell and Developmental Biology
233 papers in training set
Top 5%
0.8%
29
PeerJ
308 papers in training set
Top 11%
0.8%
30
Cell Reports
1498 papers in training set
Top 27%
0.8%